Slide 1: Third Quarter 2020 Earnings Call
Third Quarter 2020 Earnings Call November 4, 2020
Slide 2: 3Q 2020 Earnings Call Agenda
3Q 2020 Earnings Call Agenda Introduction Mark Johnson | Vice President, Investor Relations CEO Opening Remarks Steve Davis | Chief Executive Officer Commercial Update Michael Yang | Chief Commercial Officer R&D Update Serge Stankovic, M.D., M.S.P.H | President Financial Update Elena Ridloff | Chief
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future r
Slide 4: Opening Remarks
Opening Remarks Steve Davis CEO 4
Slide 5: Acadia Strategic Pillars: Building a Leading CNS Platform
Acadia Strategic Pillars Drive Deliver Develop NUPLAZID® On the DRP Innovative Treatments Growth in PDP Opportunity in CNS Building a Leading CNS Platform PDP = Parkinson’s disease psychosis; DRP = Dementia-related psychosis NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the tre
Slide 6: Drive NUPLAZID Growth in PDP
Drive NUPLAZID® Growth in PDP ✓ 3Q 2020 Net Sales $120.6M; +27% YoY ✓ Strong Commercial Execution Driven by Best-in-Class Virtual Engagement and In-Person Interactions ✓ FY2020 Net Sales Guidance $430 - $450M; +30% YoY1 1YoY growth number based on mid-point of the guidance range. NUPLAZID (pimavanse
Slide 7: Deliver on the DRP Opportunity
Deliver on the DRP Opportunity High Unmet Need1: sNDA PDUFA Date: April 3, 2021 • No FDA-approved treatments for DRP Pivotal Efficacy • ~2.4 million dementia patients with psychosis and ~1.2 million are treated • ~2/3 treated with off-label antipsychotics Positive Phase 3 HARMONY Study in DRP Seriou
Slide 8: Develop Innovative Treatments in CNS
Develop Innovative Treatments in CNS Program Indication Phase 1 Phase 2 Phase 3 Registration Marketed NUPLAZID® Parkinson’s Disease (pimavanserin)* Psychosis Dementia-Related Pimavanserin Psychosis Negative Symptoms of Pimavanserin Schizophrenia Trofinetide** Rett Syndrome ACP-044 Acute and Chronic
Slide 9: Commercial Update
Commercial Update Michael Yang Chief Commercial Officer 9
Slide 10: Strong Commercial Execution in PDP
Strong Commercial Execution in PDP Net Sales (in millions) 3Q20 Highlights $130 $120 $110 • Continued momentum in new patient additions $100 and revenue growth $90 $80 • Consistently high monthly fulfillment rates for $70 new and continuing patients $60 $50 • Continued growth in specialty pharmacy c
Slide 11: DRP Disease Education
DRP Disease Education MoreThanCognition.com: Disease Education Site Medical Education Film: “SPARK - Robin Williams and his Battle with Lewy Body Dementia©” In partnership with the LBDA, Acadia has sponsored a disease education adaptation of the documentary, “Robin’s Wish©” Leveraging Virtual Medica
Slide 12: R&D Update
R&D Update Serge Stankovic President 12
Slide 13: Upcoming and Recent Milestones
Upcoming and Recent Milestones EXPECTED COMPOUND INDICATION MILESTONE TIMING Dementia-Related Pimavanserin Psychosis PDUFA Date April 3, 2021 Negative Symptoms of Pimavanserin Schizophrenia Initiate ADVANCE-2 Study ✓3Q20 Trofinetide Rett Syndrome LAVENDER Study Results Expected 2H21 ACP-044 Acute an
Slide 14: ACP-044 for Acute and Chronic Pain
ACP-044 for Acute and Chronic Pain ACP-044: Preclinical Efficacy ACP-044 is a Reactive Species Decomposition Accelerant (RSDAx), a first-in-class, non-opioid, mechanism of action • Compelling activity in animal models in both focused on interrupting pathways that sensitize neurons to pain. acute and
Slide 15: Pimavanserin Data Presented at CTAD 2020
Pimavanserin Data Presented at CTAD 2020 Oral Presentations: Impact of Pimavanserin on Cognitive Measures in Patients with Neurodegenerative Disease: Results from 4 Placebo-Controlled Clinical Studies. • Presenting Author: Dr. Clive Ballard, University of Exeter Medical School Relationship Between P
Slide 16: Pimavanserin Data Presented at MDS 2020
Pimavanserin Data Presented at MDS 2020 All-Cause Mortality in Pimavanserin and Atypical Antipsychotic Users with Parkinson’s Disease in Medicare A retrospective cohort study of Parkinson’s disease patients initiating pimavanserin (n=3,227) or atypical antipsychotics (n=18,448, quetiapine 78% of use
Slide 17: Finance Update
Finance Update Elena Ridloff Chief Financial Officer 17
Slide 18: 3Q 2020 Financial Highlights
3Q 2020 Financial Highlights 3Q20 3Q19 YoY Change (GAAP) (GAAP) Total Revenue $120.6 $94.6 +27% Cost of Product Sales, License Fees and Royalties $4.8 $4.7 +2% R&D $120.1 $62.6 +92% SG&A $81.6 $72.7 +12% Net Loss $84.7 $42.0 +102% Weighted Average Basic Shares Outstanding 158.1 145.9 +8% EPS ($0.54)
Slide 19: FY2020 Financial Guidance
FY2020 Financial Guidance Previous Guidance Updated Guidance FY 2020 (8/5/2020) (11/4/2020) NUPLAZID® Net Sales $430 to $450M $430 to $450M GAAP R&D Expense $265 to $280M $325 to $340M GAAP SG&A Expense $400 to $420M $385 to $400M Non-Cash Stock-Based Compensation Expense $90 to $100M $80 to $90M Pr
Slide 20: Closing Remarks
Closing Remarks Steve Davis CEO 20
Slide 21: Near and Long-term Value Creation
Near and Long-term Value Creation Develop Innovative Treatments for Unmet Needs Deliver DRP Opportunity Advancing Pipeline & to the Market Expanding Through Business Development Drive NUPLAZID® PDUFA Date: Growth in PDP April 3, 2021 $430 - $450M FY2020 Net Sales Guidance PDP = Parkinson’s disease p
Slide 22: Q&A
Q&A